AUSTIN, TX – [Date] – Hanger Inc., a preeminent provider of orthotic and prosthetic (O&P) patient care services and solutions, has announced a pivotal strategic move with the acquisition of Liberating Technologies Inc. (LTI). This acquisition, which completes Hanger’s integration of the full Coapt portfolio, signifies a profound commitment to advancing research and development, accelerating the creation of next-generation prosthetic technologies, and ultimately enhancing the quality of life for O&P patients worldwide. LTI, a distinguished research organization established in 2000 and previously owned by Coapt, brings to Hanger a wealth of specialized expertise and a proven track record in securing and executing high-impact, government-funded initiatives aimed at pushing the boundaries of prosthetic innovation.
The strategic integration of LTI into the Hanger ecosystem, specifically under the umbrella of Hanger Ventures and the Hanger Institute for Clinical Research and Education, is anticipated to create a powerful synergy. This union will combine LTI’s deep research capabilities with Hanger’s extensive clinical network and patient data, fostering an environment ripe for rapid translational research and evidence-based advancements in clinical practice. The move underscores Hanger’s vision to lead the O&P industry not just in patient care delivery, but also in the foundational scientific and technological breakthroughs that define the future of prosthetic solutions.
Main Facts: A New Era for Prosthetic Innovation
Hanger Inc.’s acquisition of Liberating Technologies Inc. marks a significant milestone in the orthotics and prosthetics sector. This strategic maneuver is designed to profoundly strengthen Hanger’s internal research and innovation capabilities, directly impacting the speed and scope of development for advanced prosthetic technologies. LTI, renowned for its cutting-edge research and development in the O&P field, particularly through numerous government-funded grants since 2008, will now operate as a core component of Hanger’s innovation infrastructure.
The primary objective behind this acquisition is multifold: to bolster Hanger’s commitment to expanding research and development, to accelerate progress in clinical practice, and to ultimately improve patient outcomes through the application of evidence-based care. By bringing LTI’s specialized research team and their ongoing, high-impact projects into the fold, Hanger is positioning itself at the forefront of technological advancement in the O&P space. These projects include pioneering work in voice-recognition technology for enhanced prosthesis control, the development of sophisticated socket cooling systems crucial for residual limb skin health, and the optimization of electrode configurations to refine pattern recognition control, thereby maximizing functional outcomes for prosthesis users.
This acquisition is not merely a corporate transaction but a deliberate strategic investment in the future of prosthetic care. It reflects Hanger’s ambition to become the central nexus for global technological progress in O&P, fostering collaborations and driving the next wave of innovation that will directly benefit individuals living with limb loss or limb difference. The integration promises to provide LTI with unparalleled access to technical resources, invaluable clinical insights, and a vast repository of clinical data, all of which are essential for driving and enhancing innovation from concept to patient application.
Chronology: A Strategic Trajectory Towards Integrated Innovation
The acquisition of Liberating Technologies Inc. by Hanger Inc. is the culmination of a deliberate, multi-year strategic vision, deeply rooted in Hanger’s commitment to integrated innovation. This latest development follows a significant precursor event that set the stage for LTI’s incorporation into the Hanger family.
Early 2000s: The Genesis of Liberating Technologies Inc.
LTI was founded in 2000, emerging as a dedicated research organization focused on addressing complex challenges within the orthotics and prosthetics domain. From its inception, LTI distinguished itself through its singular focus on research and development, often operating at the intersection of academia, government funding, and industry application. Its early years were characterized by foundational work that laid the groundwork for its later success in securing competitive grants.
2008 Onwards: A Decade of Government-Funded Research
A pivotal period for LTI began around 2008, when its specialized research team successfully secured numerous government-funded grants. These grants, often from prestigious bodies such as the National Institutes of Health (NIH), the Department of Defense (DoD), or the Department of Veterans Affairs (VA), provided the financial and intellectual capital necessary for LTI to pursue "cutting-edge, high-impact concepts." This era saw LTI develop and refine next-generation technologies that aimed to significantly improve the functionality, comfort, and user experience of prosthetic devices. Its reputation grew within specialized research circles as a hub for advanced solutions.
Pre-2025: LTI Under Coapt Ownership
Prior to its direct acquisition by Hanger, LTI was owned by Coapt. Coapt itself is known for its pioneering work in advanced prosthetic control systems, particularly in the realm of intuitive myoelectric control. This ownership period likely fostered a synergistic relationship, where LTI’s foundational research could inform Coapt’s product development, and vice-versa. This established a natural pathway for both entities to contribute to the evolving landscape of prosthetic technology.
2025: Hanger Announces Acquisition of Coapt
A crucial antecedent to the LTI acquisition was Hanger Inc.’s announcement in 2025 regarding its impending acquisition of Coapt. This move signaled Hanger’s clear intent to integrate advanced prosthetic control technologies directly into its clinical offerings. The acquisition of Coapt was a strategic play to bring cutting-edge intuitive control systems, which translate muscle signals into precise prosthetic movements, directly to Hanger’s vast patient network. This set the stage for a deeper integration of research and development.
Current Acquisition: Completing the Coapt Portfolio and Beyond
The latest announcement confirms the acquisition of Liberating Technologies Inc., completing the full integration of the Coapt portfolio into the Hanger family. While Coapt focused on commercializing control systems, LTI represented the pure research engine that often fed such innovations. By acquiring LTI directly, Hanger ensures that the foundational research capabilities, the specialized talent, and the pipeline of future innovations that were part of the broader Coapt ecosystem are now entirely under Hanger’s direct stewardship. This ensures continuity of LTI’s ongoing grant-funded projects and provides Hanger with an unparalleled internal resource for long-term strategic research and development. This phased acquisition strategy underscores Hanger’s methodical approach to consolidating advanced O&P technologies and research into its core operations, ultimately aiming to create a comprehensive, vertically integrated innovation and care delivery model.
Supporting Data: Deep Dive into LTI’s Transformative Research
The true value of Liberating Technologies Inc. lies in its profound contributions to prosthetic science and its active portfolio of high-impact research projects. Since 2008, LTI has consistently attracted significant government funding, a testament to the recognized importance and potential of its work within the scientific and medical communities. These grants often entail rigorous peer review, indicating that LTI’s research methodologies and objectives are considered robust, innovative, and critically relevant to advancing patient care.
LTI’s ongoing initiatives, now integrated into Hanger’s R&D framework, are poised to address some of the most pressing challenges faced by individuals using prostheses:
Advancing Voice-Recognition Technology for Improved Prosthesis Control
One of LTI’s flagship projects involves pioneering advancements in voice-recognition technology specifically tailored for prosthesis control. Traditional myoelectric prostheses rely on muscle signals, which can be inconsistent, difficult to master, and limited in the number of discrete commands they can execute. Voice control offers an intuitive alternative or supplement, potentially allowing users to issue complex commands naturally, reducing cognitive load, and improving precision. Imagine a user simply saying "grasp" or "rotate wrist" and the prosthesis responding accurately.
This research focuses on developing robust algorithms that can differentiate between spoken commands in various environments (noisy, quiet), adapt to individual speech patterns, and translate these commands into seamless, real-time prosthetic movements. The challenges include minimizing latency, ensuring high accuracy, and creating a user-friendly interface that integrates smoothly with other control modalities. Success in this area could significantly enhance the independence and functional capabilities of upper-limb prosthesis users, offering a more intuitive and less fatiguing way to interact with their devices.
Developing Socket Cooling Systems to Support Residual Limb Skin Health
A pervasive and often debilitating issue for lower-limb prosthesis users is the health of their residual limb skin. The socket, while essential for support and control, creates a warm, moist, and often abrasive environment. This can lead to skin breakdown, ulcers, infections, and discomfort, significantly limiting wear time and overall quality of life. Current solutions are often reactive or involve frequent removal of the prosthesis.
LTI’s research into socket cooling systems aims to proactively mitigate these issues. This involves exploring innovative materials, active cooling technologies (e.g., miniature thermoelectric coolers, advanced phase-change materials, or even micro-fluidic systems), and intelligent sensors that monitor temperature and humidity within the socket. The goal is to create a dynamic system that maintains an optimal microclimate, preventing excessive sweating and heat buildup. Such a system would not only improve comfort but critically reduce the incidence of skin complications, allowing users to wear their prostheses for longer durations with greater confidence and reduced risk of injury. This represents a major leap in enhancing the long-term health and usability of prosthetic devices.
Optimizing Electrode Configurations for Pattern Recognition Control
Pattern recognition control represents a significant advancement over conventional myoelectric control. Instead of relying on a few discrete muscle sites for simple open/close commands, pattern recognition algorithms analyze complex electrical signals from multiple muscle groups in the residual limb. By "learning" the unique electrical patterns associated with different intended movements (e.g., wrist flexion, hand rotation, specific grasp types), these systems can provide much more intuitive and versatile control over multi-articulated prostheses.
LTI’s work in this area focuses on optimizing the placement, number, and type of electrodes, as well as refining the underlying algorithms. This includes exploring high-density electrode arrays, novel electrode materials, and advanced machine learning techniques to improve the accuracy, robustness, and adaptability of pattern recognition systems. Challenges include signal stability, dealing with muscle fatigue, and ensuring reliable performance across a wide range of tasks and environmental conditions. By perfecting these configurations, LTI aims to unlock the full potential of pattern recognition, allowing prosthesis users to achieve more natural, precise, and complex movements, thereby significantly improving their functional outcomes and integration of the prosthesis into daily life. This research directly contributes to making advanced prostheses feel more like an extension of the body rather than a separate tool.
These projects exemplify LTI’s dedication to foundational and applied research that directly translates into tangible benefits for patients. Their integration into Hanger provides a direct pathway from laboratory discovery to clinical implementation, leveraging Hanger’s vast network of O&P clinics and patient insights to guide and validate research efforts.
Official Responses: A United Vision for the Future
The leadership of Hanger Inc. has articulated a clear and enthusiastic vision regarding the acquisition of Liberating Technologies Inc., emphasizing the strategic alignment and the profound potential for transforming patient care. Their statements underscore a commitment to innovation that extends beyond clinical services into the very foundations of prosthetic technology.
Pete Stoy, Hanger’s Chief Executive Officer, highlighted the acquisition as a cornerstone of the company’s broader strategic objectives. "The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," Stoy remarked. His statement points to a holistic approach where R&D is not an isolated endeavor but an integral part of enhancing the entire patient journey. This commitment is particularly significant in the O&P field, where technological advancements can dramatically alter a patient’s independence and quality of life.
Stoy further elaborated on the global implications of this partnership: "This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation." This indicates Hanger’s intent to be a catalyst for change on an international scale, potentially fostering broader industry collaborations and setting new benchmarks for prosthetic technology. By bringing LTI’s specialized research capabilities in-house, Hanger gains direct control over a critical innovation pipeline, allowing it to dictate the pace and direction of future advancements. The emphasis on "joining forces with current and future collaborators" suggests an open innovation model, where Hanger aims to leverage its strengthened R&D capabilities to attract and partner with other leading minds and institutions in the field.
Todd Farrell, PhD, who serves as vice president of research and development for Hanger, provided insights into the immediate and tangible benefits of LTI joining the Hanger ecosystem. His perspective, coming from a research and development background, illuminates the practical synergies. "We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation," Dr. Farrell stated.
Dr. Farrell’s comments highlight the critical resources that Hanger brings to LTI. While LTI has excelled at securing government grants and conducting cutting-edge research, the direct access to Hanger’s extensive clinical network is invaluable. This network provides a direct conduit to real-world patient experiences, diverse anatomical data, and clinical feedback—all essential for refining research hypotheses and validating prototype designs. The ability to test innovations in a controlled clinical environment, gather real-time data, and iterate quickly based on patient outcomes will significantly accelerate the development cycle. Furthermore, Hanger’s technical resources, which likely include advanced manufacturing capabilities, engineering expertise, and sophisticated analytical tools, will empower LTI to translate laboratory discoveries into viable clinical solutions more efficiently. This symbiotic relationship promises to bridge the gap between theoretical research and practical application, a common challenge in specialized medical fields.
Collectively, these official responses paint a picture of a strategically astute acquisition designed to consolidate expertise, accelerate innovation, and ultimately solidify Hanger’s position as a leader not just in O&P care, but also in the foundational science that drives its evolution. The enthusiasm from both the CEO and the head of R&D underscores the perceived value and transformative potential of LTI’s integration.
Implications: Reshaping the Landscape of Prosthetic Care
The acquisition of Liberating Technologies Inc. by Hanger Inc. carries profound implications for the orthotics and prosthetics industry, for Hanger’s strategic trajectory, and most importantly, for the patients who rely on these life-changing devices. This move is not merely an expansion of Hanger’s portfolio but a deliberate attempt to reshape the future of prosthetic care through integrated innovation.
Impact on the O&P Industry and Market Leadership
Hanger Inc. is already a dominant force in the O&P sector, boasting an expansive network of clinics and a reputation for comprehensive patient care. By bringing LTI’s advanced research capabilities in-house, Hanger is solidifying its position not just as a service provider but as a full-spectrum innovation hub. This could set a new industry standard, potentially compelling competitors to invest more heavily in their own R&D or seek similar partnerships. The vertical integration of cutting-edge research with extensive clinical delivery creates a powerful competitive advantage, allowing Hanger to be among the first to bring truly transformative technologies from concept to patient. This move could accelerate the pace of innovation across the entire industry, fostering a more dynamic and competitive environment that ultimately benefits patients.
Accelerated Innovation and Product Development
The most direct implication is a significant acceleration in the development and deployment of next-generation prosthetic technologies. LTI’s ongoing projects, such as voice-recognition control, socket cooling systems, and optimized pattern recognition, represent critical advancements. With Hanger’s vast resources, clinical data, and direct patient access, LTI can transition from research to clinical validation and eventual commercialization more rapidly and effectively. This synergy means that patients could see tangible improvements in comfort, control, and functionality of their prostheses much sooner. The "Hanger ecosystem" provides a streamlined pathway for innovations, reducing the typical lag between scientific discovery and practical application.
Enhanced Patient Outcomes and Quality of Life
Ultimately, the success of this acquisition will be measured by its impact on patients. The technologies LTI is developing directly address critical pain points and limitations in current prosthetic use.
- Improved control: Voice recognition and optimized pattern recognition will make prostheses more intuitive and less fatiguing to operate, enhancing a user’s independence and ability to perform daily tasks with greater precision.
- Enhanced comfort and health: Socket cooling systems will drastically improve residual limb health, reducing skin breakdown, discomfort, and the need for frequent adjustments or repairs. This means longer wear times, fewer complications, and a significantly better overall experience.
- Personalization: The data and insights gathered from Hanger’s clinical network, combined with LTI’s research, could lead to more personalized prosthetic solutions, tailored to individual patient needs, anatomies, and lifestyles.
These advancements collectively promise a substantial uplift in the quality of life for individuals with limb loss or limb difference, moving beyond mere replacement towards true functional integration and comfort.
Strategic Alignment and Future Growth
This acquisition is perfectly aligned with Hanger’s long-term strategic vision to remain at the forefront of orthotics and prosthetics. It demonstrates a forward-thinking approach that recognizes the critical role of technology and research in defining future healthcare solutions. By integrating LTI, Hanger is not just acquiring technology but intellectual capital and a culture of relentless inquiry. This will likely attract top talent in O&P research and engineering, further bolstering Hanger’s innovation pipeline.
Furthermore, this move positions Hanger for future growth in an evolving healthcare landscape. As demographics shift and medical advancements enable more active lifestyles for individuals with limb loss, the demand for sophisticated, comfortable, and highly functional prostheses will only increase. By investing in foundational research now, Hanger is ensuring its relevance and leadership in the market for decades to come.
Potential for Broader Collaborations
The stated ambition to "join forces with current and future collaborators" suggests that Hanger, now fortified with LTI’s research prowess, may become an even more attractive partner for academic institutions, government agencies, and other technology companies. This could lead to a broader ecosystem of innovation, where Hanger plays a central role in facilitating cross-disciplinary research and development, ultimately benefiting the entire O&P community and patients globally.
In conclusion, Hanger Inc.’s acquisition of Liberating Technologies Inc. is far more than a corporate transaction; it is a strategic declaration of intent. It signals a new era where the profound expertise of a dedicated research organization is seamlessly integrated with the expansive clinical reach of an industry leader. This union promises not only to accelerate the development of groundbreaking prosthetic technologies but also to fundamentally transform the daily lives of countless individuals, setting a new standard for innovation and patient care in the orthotics and prosthetics field.
